Cravens & CO Advisors, LLC Regeneron Pharmaceuticals, Inc. Transaction History
Cravens & CO Advisors, LLC
- $129 Billion
- Q3 2024
A detailed history of Cravens & CO Advisors, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Cravens & CO Advisors, LLC holds 1,305 shares of REGN stock, worth $915,914. This represents 1.06% of its overall portfolio holdings.
Number of Shares
1,305
Previous 1,234
5.75%
Holding current value
$915,914
Previous $1.3 Billion
5.77%
% of portfolio
1.06%
Previous 0.96%
Shares
8 transactions
Others Institutions Holding REGN
# of Institutions
1,534Shares Held
83.6MCall Options Held
1.22MPut Options Held
1.51M-
Vanguard Group Inc Valley Forge, PA9.32MShares$6.54 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$5.93 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.49MShares$5.26 Billion0.65% of portfolio
-
State Street Corp Boston, MA4.9MShares$3.44 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.3MShares$3.02 Billion0.72% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $75.2B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...